CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
High ImpactOriginal article

BIVIGAM

RegulatoryapprovedBIVIGAMPositive
AI Analysis

Summary

BIVIGAM received FDA approval for the treatment of Primary Humoral Immunodeficiency. The product approval information indicates regulatory clearance for this immunodeficiency indication.

Outcome Details

Product approval information indicated for treatment of Primary Humoral Immunodeficiency

Importance:8/10
Sentiment:
0.80
FDA approvalimmunodeficiencybiologicsproduct approval

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on September 30, 2026 8:03 PM

Read Original